Mark Pykett
Director/Board Member bei PHARMING GROUP N.V.
Vermögen: 131 558 $ am 31.03.2024
Profil
Mark Jerome Pykett founded Cytomatrix in 1996, where he worked as President & Chief Executive Officer from 1996 to 2003.
Dr. Pykett also currently works at Myrtelle, Inc., as Chief Executive Officer from 2021, Inflectis Bioscience SAS, as Chairman from 2021, MyoPax GmbH, as Chairman, Pharming Group NV, as Non-Executive Director from 2020, and Exubrion Therapeutics , Inc., as Director.
Dr. Pykett also formerly worked at Navidea Biopharmaceuticals, Inc., as Chief Executive Officer & Director in 2014, Agilis Biotherapeutics LLC, as President, Chief Executive Officer & Director from 2014 to 2018, Mast Therapeutics, Inc., as Director in 2004, Health Builders International, Inc., as Director, Oramax LLC, as Director from 2000 to 2006, Alseres Pharmaceuticals, Inc., as President & Chief Operating Officer from 2004 to 2010, PTC Therapeutics, Inc., as Chief Scientific Officer from 2018 to 2021, CyGenics Ltd., as President in 2004, and Cordlife Group Ltd., as President in 2005.
Dr. Pykett received his doctorate degree from the University of Pennsylvania, undergraduate degree from Amherst College, Masters Business Admin degree from Northeastern University, and doctorate degree from the University of Pennsylvania School of Veterinary Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PHARMING GROUP NV
0,02% | 31.03.2024 | 119 542 ( 0,02% ) | 131 558 $ | 31.03.2024 |
Aktive Positionen von Mark Pykett
| Unternehmen | Position | Beginn |
|---|---|---|
| PHARMING GROUP N.V. | Director/Board Member | 11.12.2020 |
| Myrtelle, Inc. | Chief Executive Officer | 01.01.2021 |
Exubrion Therapeutics , Inc.
 Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Director/Board Member | - |
Inflectis Bioscience SAS
 Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Chairman | 04.10.2021 |
MyoPax GmbH
 MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | Chairman | - |
Ehemalige bekannte Positionen von Mark Pykett
| Unternehmen | Position | Ende |
|---|---|---|
| PTC THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2021 |
Agilis Biotherapeutics LLC
 Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.01.2018 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Chief Executive Officer | 30.05.2014 |
| ALSERES PHARMACEUTICALS, INC. | President | 04.01.2010 |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mark Pykett
| University of Pennsylvania | Doctorate Degree |
| Amherst College | Undergraduate Degree |
| Northeastern University | Masters Business Admin |
| University of Pennsylvania School of Veterinary Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| ALSERES PHARMACEUTICALS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| CORDLIFE GROUP LIMITED | Health Services |
| PHARMING GROUP N.V. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
| CyGenics Ltd. | Commercial Services |
Agilis Biotherapeutics LLC
Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Health Builders International, Inc.
 Health Builders International, Inc. Financial ConglomeratesFinance Health Builders International, Inc. is an American development stage company. | Finance |
Cytomatrix
 Cytomatrix Miscellaneous Commercial ServicesCommercial Services Part of Cordlife Group Ltd., Cytomatrix is a private company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million. | Commercial Services |
| Oramax LLC | |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | Health Technology |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | Health Technology |
MyoPax GmbH
MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | Health Technology |
| Myrtelle, Inc. |
